Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Identifieur interne : 002A31 ( Main/Exploration ); précédent : 002A30; suivant : 002A32Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
Auteurs : Nicholas C. Turner [Australie] ; Jungsil Ro ; Fabrice André ; Sherene Loi ; Sunil Verma ; Hiroji Iwata ; Nadia Harbeck ; Sibylle Loibl ; Cynthia Huang Bartlett ; Ke Zhang ; Carla Giorgetti ; Sophia Randolph ; Maria Koehler ; Massimo CristofanilliSource :
- The New England journal of medicine [ 1533-4406 ] ; 2015.
Descripteurs français
- KwdFr :
- Adulte, Adulte d'âge moyen, Femelle, Humains, Inhibiteurs de protéines kinases (effets indésirables), Inhibiteurs de protéines kinases (usage thérapeutique), Kinase-4 cycline-dépendante (antagonistes et inhibiteurs), Kinase-6 cycline-dépendante (antagonistes et inhibiteurs), Marqueurs biologiques (analyse), Méthode en double aveugle, Oestradiol (analogues et dérivés), Oestradiol (effets indésirables), Oestradiol (usage thérapeutique), Pipérazines (effets indésirables), Pipérazines (usage thérapeutique), Protocoles de polychimiothérapie antinéoplasique (effets indésirables), Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique), Pyridines (effets indésirables), Pyridines (usage thérapeutique), Récepteur ErbB-2 (analyse), Récepteurs des oestrogènes (analyse), Récepteurs à la progestérone (analyse), Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute, Tumeurs du sein (traitement médicamenteux).
- MESH :
- analogues et dérivés : Oestradiol.
- analyse : Marqueurs biologiques, Récepteur ErbB-2, Récepteurs des oestrogènes, Récepteurs à la progestérone.
- antagonistes et inhibiteurs : Kinase-4 cycline-dépendante, Kinase-6 cycline-dépendante.
- effets indésirables : Inhibiteurs de protéines kinases, Oestradiol, Pipérazines, Protocoles de polychimiothérapie antinéoplasique, Pyridines.
- traitement médicamenteux : Tumeurs du sein.
- usage thérapeutique : Inhibiteurs de protéines kinases, Oestradiol, Pipérazines, Protocoles de polychimiothérapie antinéoplasique, Pyridines.
- Adulte, Adulte d'âge moyen, Femelle, Humains, Méthode en double aveugle, Sujet âgé, Sujet âgé de 80 ans ou plus, Survie sans rechute.
English descriptors
- KwdEn :
- Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols (adverse effects), Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Biomarkers (analysis), Breast Neoplasms (drug therapy), Cyclin-Dependent Kinase 4 (antagonists & inhibitors), Cyclin-Dependent Kinase 6 (antagonists & inhibitors), Disease-Free Survival, Double-Blind Method, Estradiol (adverse effects), Estradiol (analogs & derivatives), Estradiol (therapeutic use), Female, Humans, Middle Aged, Piperazines (adverse effects), Piperazines (therapeutic use), Protein Kinase Inhibitors (adverse effects), Protein Kinase Inhibitors (therapeutic use), Pyridines (adverse effects), Pyridines (therapeutic use), Receptor, ErbB-2 (analysis), Receptors, Estrogen (analysis), Receptors, Progesterone (analysis).
- MESH :
- chemical , adverse effects : Estradiol, Piperazines, Protein Kinase Inhibitors, Pyridines.
- chemical , analogs & derivatives : Estradiol.
- chemical , analysis : Biomarkers, Receptor, ErbB-2, Receptors, Estrogen, Receptors, Progesterone.
- adverse effects : Antineoplastic Combined Chemotherapy Protocols.
- chemical , antagonists & inhibitors : Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6.
- drug therapy : Breast Neoplasms.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols, Estradiol, Piperazines, Protein Kinase Inhibitors, Pyridines.
- Adult, Aged, Aged, 80 and over, Disease-Free Survival, Double-Blind Method, Female, Humans, Middle Aged.
Abstract
Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.
DOI: 10.1056/NEJMoa1505270
PubMed: 26030518
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 002C14
- to stream PubMed, to step Curation: 002B41
- to stream PubMed, to step Checkpoint: 002B41
- to stream Ncbi, to step Merge: 002646
- to stream Ncbi, to step Curation: 002646
- to stream Ncbi, to step Checkpoint: 002646
- to stream Main, to step Merge: 002A31
- to stream Main, to step Curation: 002A31
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.</title><author><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name><affiliation wicri:level="4"><nlm:affiliation>From Royal Marsden Hospital, London (N.C.T.); National Cancer Center, Goyang-si, South Korea (J.R.); Institut Gustave Roussy, Villejuif, France (F.A.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Sunnybrook Odette Cancer Centre, Toronto (S.V.); Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); Brustzentrum der Universität München, Munich (N.H.), and German Breast Group Forschungs, Neu-Isenburg (S. Loibl) - both in Germany; Pfizer, New York (C.H.B., M.K.), La Jolla, CA (K.Z., S.R.), and Milan (C.G.); and Thomas Jefferson University, Philadelphia (M.C.).</nlm:affiliation><orgName type="university">Université de Melbourne</orgName><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Ro, Jungsil" sort="Ro, Jungsil" uniqKey="Ro J" first="Jungsil" last="Ro">Jungsil Ro</name></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name></author><author><name sortKey="Verma, Sunil" sort="Verma, Sunil" uniqKey="Verma S" first="Sunil" last="Verma">Sunil Verma</name></author><author><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name></author><author><name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name></author><author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name></author><author><name sortKey="Huang Bartlett, Cynthia" sort="Huang Bartlett, Cynthia" uniqKey="Huang Bartlett C" first="Cynthia" last="Huang Bartlett">Cynthia Huang Bartlett</name></author><author><name sortKey="Zhang, Ke" sort="Zhang, Ke" uniqKey="Zhang K" first="Ke" last="Zhang">Ke Zhang</name></author><author><name sortKey="Giorgetti, Carla" sort="Giorgetti, Carla" uniqKey="Giorgetti C" first="Carla" last="Giorgetti">Carla Giorgetti</name></author><author><name sortKey="Randolph, Sophia" sort="Randolph, Sophia" uniqKey="Randolph S" first="Sophia" last="Randolph">Sophia Randolph</name></author><author><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name></author><author><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2015">2015</date><idno type="RBID">pubmed:26030518</idno><idno type="pmid">26030518</idno><idno type="doi">10.1056/NEJMoa1505270</idno><idno type="wicri:Area/PubMed/Corpus">002C14</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002C14</idno><idno type="wicri:Area/PubMed/Curation">002B41</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002B41</idno><idno type="wicri:Area/PubMed/Checkpoint">002B41</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002B41</idno><idno type="wicri:Area/Ncbi/Merge">002646</idno><idno type="wicri:Area/Ncbi/Curation">002646</idno><idno type="wicri:Area/Ncbi/Checkpoint">002646</idno><idno type="wicri:Area/Main/Merge">002A31</idno><idno type="wicri:Area/Main/Curation">002A31</idno><idno type="wicri:Area/Main/Exploration">002A31</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.</title><author><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name><affiliation wicri:level="4"><nlm:affiliation>From Royal Marsden Hospital, London (N.C.T.); National Cancer Center, Goyang-si, South Korea (J.R.); Institut Gustave Roussy, Villejuif, France (F.A.); Peter MacCallum Cancer Centre, University of Melbourne, Melbourne, VIC, Australia (S. Loi); Sunnybrook Odette Cancer Centre, Toronto (S.V.); Aichi Cancer Center Hospital, Nagoya, Japan (H.I.); Brustzentrum der Universität München, Munich (N.H.), and German Breast Group Forschungs, Neu-Isenburg (S. Loibl) - both in Germany; Pfizer, New York (C.H.B., M.K.), La Jolla, CA (K.Z., S.R.), and Milan (C.G.); and Thomas Jefferson University, Philadelphia (M.C.).</nlm:affiliation><orgName type="university">Université de Melbourne</orgName><country>Australie</country><placeName><settlement type="city">Melbourne</settlement><region type="état">Victoria (État)</region></placeName></affiliation></author><author><name sortKey="Ro, Jungsil" sort="Ro, Jungsil" uniqKey="Ro J" first="Jungsil" last="Ro">Jungsil Ro</name></author><author><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name></author><author><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name></author><author><name sortKey="Verma, Sunil" sort="Verma, Sunil" uniqKey="Verma S" first="Sunil" last="Verma">Sunil Verma</name></author><author><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name></author><author><name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name></author><author><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name></author><author><name sortKey="Huang Bartlett, Cynthia" sort="Huang Bartlett, Cynthia" uniqKey="Huang Bartlett C" first="Cynthia" last="Huang Bartlett">Cynthia Huang Bartlett</name></author><author><name sortKey="Zhang, Ke" sort="Zhang, Ke" uniqKey="Zhang K" first="Ke" last="Zhang">Ke Zhang</name></author><author><name sortKey="Giorgetti, Carla" sort="Giorgetti, Carla" uniqKey="Giorgetti C" first="Carla" last="Giorgetti">Carla Giorgetti</name></author><author><name sortKey="Randolph, Sophia" sort="Randolph, Sophia" uniqKey="Randolph S" first="Sophia" last="Randolph">Sophia Randolph</name></author><author><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name></author><author><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name></author></analytic><series><title level="j">The New England journal of medicine</title><idno type="eISSN">1533-4406</idno><imprint><date when="2015" type="published">2015</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Antineoplastic Combined Chemotherapy Protocols (adverse effects)</term><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Biomarkers (analysis)</term><term>Breast Neoplasms (drug therapy)</term><term>Cyclin-Dependent Kinase 4 (antagonists & inhibitors)</term><term>Cyclin-Dependent Kinase 6 (antagonists & inhibitors)</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Estradiol (adverse effects)</term><term>Estradiol (analogs & derivatives)</term><term>Estradiol (therapeutic use)</term><term>Female</term><term>Humans</term><term>Middle Aged</term><term>Piperazines (adverse effects)</term><term>Piperazines (therapeutic use)</term><term>Protein Kinase Inhibitors (adverse effects)</term><term>Protein Kinase Inhibitors (therapeutic use)</term><term>Pyridines (adverse effects)</term><term>Pyridines (therapeutic use)</term><term>Receptor, ErbB-2 (analysis)</term><term>Receptors, Estrogen (analysis)</term><term>Receptors, Progesterone (analysis)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Inhibiteurs de protéines kinases (effets indésirables)</term><term>Inhibiteurs de protéines kinases (usage thérapeutique)</term><term>Kinase-4 cycline-dépendante (antagonistes et inhibiteurs)</term><term>Kinase-6 cycline-dépendante (antagonistes et inhibiteurs)</term><term>Marqueurs biologiques (analyse)</term><term>Méthode en double aveugle</term><term>Oestradiol (analogues et dérivés)</term><term>Oestradiol (effets indésirables)</term><term>Oestradiol (usage thérapeutique)</term><term>Pipérazines (effets indésirables)</term><term>Pipérazines (usage thérapeutique)</term><term>Protocoles de polychimiothérapie antinéoplasique (effets indésirables)</term><term>Protocoles de polychimiothérapie antinéoplasique (usage thérapeutique)</term><term>Pyridines (effets indésirables)</term><term>Pyridines (usage thérapeutique)</term><term>Récepteur ErbB-2 (analyse)</term><term>Récepteurs des oestrogènes (analyse)</term><term>Récepteurs à la progestérone (analyse)</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term><term>Tumeurs du sein (traitement médicamenteux)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Estradiol</term><term>Piperazines</term><term>Protein Kinase Inhibitors</term><term>Pyridines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Estradiol</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analysis" xml:lang="en"><term>Biomarkers</term><term>Receptor, ErbB-2</term><term>Receptors, Estrogen</term><term>Receptors, Progesterone</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Oestradiol</term></keywords><keywords scheme="MESH" qualifier="analyse" xml:lang="fr"><term>Marqueurs biologiques</term><term>Récepteur ErbB-2</term><term>Récepteurs des oestrogènes</term><term>Récepteurs à la progestérone</term></keywords><keywords scheme="MESH" qualifier="antagonistes et inhibiteurs" xml:lang="fr"><term>Kinase-4 cycline-dépendante</term><term>Kinase-6 cycline-dépendante</term></keywords><keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>Cyclin-Dependent Kinase 4</term><term>Cyclin-Dependent Kinase 6</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Breast Neoplasms</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Oestradiol</term><term>Pipérazines</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term><term>Estradiol</term><term>Piperazines</term><term>Protein Kinase Inhibitors</term><term>Pyridines</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Tumeurs du sein</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Inhibiteurs de protéines kinases</term><term>Oestradiol</term><term>Pipérazines</term><term>Protocoles de polychimiothérapie antinéoplasique</term><term>Pyridines</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Disease-Free Survival</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Middle Aged</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adulte</term><term>Adulte d'âge moyen</term><term>Femelle</term><term>Humains</term><term>Méthode en double aveugle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Survie sans rechute</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Growth of hormone-receptor-positive breast cancer is dependent on cyclin-dependent kinases 4 and 6 (CDK4 and CDK6), which promote progression from the G1 phase to the S phase of the cell cycle. We assessed the efficacy of palbociclib (an inhibitor of CDK4 and CDK6) and fulvestrant in advanced breast cancer.</div></front></TEI><affiliations><list><country><li>Australie</li></country><region><li>Victoria (État)</li></region><settlement><li>Melbourne</li></settlement><orgName><li>Université de Melbourne</li></orgName></list><tree><noCountry><name sortKey="Andre, Fabrice" sort="Andre, Fabrice" uniqKey="Andre F" first="Fabrice" last="André">Fabrice André</name><name sortKey="Cristofanilli, Massimo" sort="Cristofanilli, Massimo" uniqKey="Cristofanilli M" first="Massimo" last="Cristofanilli">Massimo Cristofanilli</name><name sortKey="Giorgetti, Carla" sort="Giorgetti, Carla" uniqKey="Giorgetti C" first="Carla" last="Giorgetti">Carla Giorgetti</name><name sortKey="Harbeck, Nadia" sort="Harbeck, Nadia" uniqKey="Harbeck N" first="Nadia" last="Harbeck">Nadia Harbeck</name><name sortKey="Huang Bartlett, Cynthia" sort="Huang Bartlett, Cynthia" uniqKey="Huang Bartlett C" first="Cynthia" last="Huang Bartlett">Cynthia Huang Bartlett</name><name sortKey="Iwata, Hiroji" sort="Iwata, Hiroji" uniqKey="Iwata H" first="Hiroji" last="Iwata">Hiroji Iwata</name><name sortKey="Koehler, Maria" sort="Koehler, Maria" uniqKey="Koehler M" first="Maria" last="Koehler">Maria Koehler</name><name sortKey="Loi, Sherene" sort="Loi, Sherene" uniqKey="Loi S" first="Sherene" last="Loi">Sherene Loi</name><name sortKey="Loibl, Sibylle" sort="Loibl, Sibylle" uniqKey="Loibl S" first="Sibylle" last="Loibl">Sibylle Loibl</name><name sortKey="Randolph, Sophia" sort="Randolph, Sophia" uniqKey="Randolph S" first="Sophia" last="Randolph">Sophia Randolph</name><name sortKey="Ro, Jungsil" sort="Ro, Jungsil" uniqKey="Ro J" first="Jungsil" last="Ro">Jungsil Ro</name><name sortKey="Verma, Sunil" sort="Verma, Sunil" uniqKey="Verma S" first="Sunil" last="Verma">Sunil Verma</name><name sortKey="Zhang, Ke" sort="Zhang, Ke" uniqKey="Zhang K" first="Ke" last="Zhang">Ke Zhang</name></noCountry><country name="Australie"><region name="Victoria (État)"><name sortKey="Turner, Nicholas C" sort="Turner, Nicholas C" uniqKey="Turner N" first="Nicholas C" last="Turner">Nicholas C. Turner</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002A31 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002A31 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:26030518
|texte= Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:26030518" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |